Antibody Drug
Conjugates (ADCs)

Antibody Drug Conjugates (ADCs) are now a well established, clinically and commercially proven form of antibody therapeutics allowing the specific tumour delivery of potent cytoxic payloads. After many years, we are seeing many product approvals with the likes of Enhertu and Tivdak driving confidence and momentum. However, despite their success, whole monoclonal antibody (MAb)-based ADCs have intrinsic failings which limit their efficacy in solid tumours, causes unacceptable dose-limiting side-effects and provides for an overall a narrow therapeutic index.

Antikor's unique Antibody Fragment Drug Conjugate (FDC) approach promises to revolutionize solid tumour therapy enabling the next-generation of ADC products in oncology and beyond.

Fragment Drug
Conjugates (FDCs)

With its revolutionary and proprietary OptiLinkTM technology platform, Antikor has adopted a novel approach using much smaller fully-human antibody fragments which can carry high payload loadings leading to a high-DAR (Drug:Antibody Ratio) FDC. This increased potency combined with superior penetration properties and faster valsculature and normal organ elimination makes for potentially best-in-class oncology therapeutics, tailored for difficult-to-treat solid tumours. Antikor's pre-clinical data demonstrate that FDCs have a much wider therapeutic window than conventional ADCs and could revolutionise the way we treat solid tumours. 

Discovery Engine
And Products

Antikor uses proprietary human antibody VH/VL frameworks, optimised for maximal stability and DAR and tailored linker-payloads to generate FDCs which have excellent developability properties. Our Discovery Engine can be used to discover novel FDCs to any given target.

This makes the Antikor FDC-optimized antibody libraries a valuable asset in its own right and the source of future, exciting new products.  


A Brief History

Antikor - Creating Antibody Drug ConjugatesAntikor Ltd is a newly established company that is exploiting a novel technology platform called OptiLinked-FDCs, to generate revolutionary products to treat solid cancers. We are a multidisciplinary spin-out from Imperial College London UK now based at the Stevenage Bioscience Catalyst. The Company has over 15 years of pioneering experience in the area of small-format, antibody fragment drug conjugates, and has generated product candidates with optimal pharmacokinetics, pharmacodynamics and other encouraging preclinical data.



Antikor is looking for commercial partners with existing or future interests in the ADC space, particulary oncology. We can offer a range of flexible models for collaboration where each party adds value to each other's technology

Are you seeking :-

Do you have:-

If the answer to any of these questions is yes, then please contact us to initiate a collaboration and licensing dialogue on Antikor's OptiLink technology platform


View All